Skip to main content
OpenTrials
Completed

NCT Number: NCT01495858

Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

The objective of the study is to evaluate the efficacy and safety of a single oral dose of naproxen sodium 440 mg in combination with DPH (diphenhydramine) 25 mg in subjects with postsurgical dental pain and phase advanced sleep.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain, Postoperative Neurologic Manifestations Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Signs and Symptoms

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Austin, Texas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, ambulatory, male and female volunteers ages 12 and older
  • Scheduled to undergo surgical removal of a minimum of two third molars of which at least one has to be a mandibular third molar. The mandibular extraction(s) required by each subject must meet one of the following scenarios:
  • one full bony impaction
  • two partial bony impactions
  • one full bony impaction and one partial bony impaction
  • one full bony impaction and one soft tissue impaction
  • one full bony impaction and one erupted third molar. Two full bony mandibular impactions are not allowed. Maxillary third molars may be removed regardless of impaction level.
  • Have moderate to severe postoperative pain on the Categorical Pain Rating Scale and a score of >/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale between 1600 hour and 1830 hour on the day of surgery
  • Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera, or double-barrier and have a negative pregnancy test at Screening and prior to surgery. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy.

Exclusion criteria

  • History of hypersensitivity to naproxen, diphenhydramine, nonsteroidal anti-inflammatory drug (NSAIDS), tramadol, aspirin or any other antihistamine and similar pharmacological agents or components of the products
  • Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study in the judgment of the investigator
  • Current or past history of bleeding disorder(s)
  • Acute illness or local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator
  • Chronic use of antihistamines defined as using 5 or more times a week for 2 or more consecutive weeks during the past 3 months
  • Positive alcohol breathalyzer test and positive urine drug test prior to surgery
  • Females who are pregnant or lactating
  • Chronic or severe sleep problems that do not respond to Over the Counter (OTC) medication and requires a prescription hypnotic or sedative
  • Habitually spends less than 6.5 hours in bed

Treatment and study plan

Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)

Drug

Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.

Naproxen sodium 440 mg (BAYH6689)

Drug

Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.

DPH 50 mg

Drug

Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.

Primary outcomes

  1. Wake Time After Sleep Onset (WASO) Measured by Actigraphy

    Time frame: Up to 10 hours

    WASO was defined as Total wake time (in minutes) after sleep onset during the 10 hours in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

  2. Sleep Latency Measured by Actigraphy

    Time frame: Up to 10 hours

    Sleep latency was defined as the time to sleep onset from the time of dosing as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

Secondary outcomes

  1. Total Sleep Time Measured by Actigraphy

    Time frame: Up to 10 hours

    Total time spent sleeping (not to exceed 600 minutes) during the in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

  2. Sleep Efficiency Measured by Actigraphy

    Time frame: Up to 10 hours

    Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

  3. Global Assessment of Investigational Product as a Sleep Aid

    Time frame: Up to 10 hours

    The Global Assessment of Investigational Product as a Sleep-Aid was rated using a 5-point categorical scale for which the potential response was poor (0), fair, (1), good (2), very good (3), or excellent (4).

  4. Karolinska Sleep Diary - Sleep Quality

    Time frame: Up to 10 hours

    Subjects responded to the following question: How was your sleep? very poor (1); rather poor (2); neither poor nor good (3); rather good (4); very good (5)

  5. Karolinska Sleep Diary - Calmness of Sleep

    Time frame: Up to 10 hours

    Subjects responded to the following question: How calm was your sleep? very restless (1); rather restless (2); neither restless nor calm (3); rather calm (4); very calm (5)

  6. Karolinska Sleep Diary - Easiness to Fall Asleep

    Time frame: Up to 10 hours

    Subjects responded to the following question: How easy was it to fall asleep? very difficult (1); rather difficult (2); neither difficult nor easy (3); rather easy (4); very easy (5)

  7. Karolinska Sleep Diary - Premature Awakening

    Time frame: Up to 10 hours

    Subjects responded to the following question : Premature awakening? woke up much too early (1); woke up somewhat too early (2); no (3)

  8. Karolinska Sleep Diary - Ease of Awakening

    Time frame: Up to 10 hours

    Subjects responded to the following question: Ease of awakening? (1) very difficult; (2) rather difficult; (3) neither difficult nor easy; (4) rather easy; very easy (5)

  9. Karolinska Sleep Diary - Well Rested

    Time frame: Up to 10 hours

    Subjects responded to the following question: Well Rested? not rested at all (1); somewhat unrested (2); completely rested (3)

  10. Karolinska Sleep Diary - Sufficient Sleep

    Time frame: Up to 10 hours

    Subjects responded to the following question: Did you get enough (sufficient) sleep? no, definitely too little (1); no, much too little (2); no, somewhat too little (3); yes, almost enough (4); yes, definitely enough (5)

  11. Subjective Sleep Questionnaire - Quality of Your Sleep Last Night

    Time frame: Up to 10 hours

    Subject evaluated sleep quality on a 10-point scale, where 1 was poor and 10 was excellent.

  12. Subjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night

    Time frame: Up to 10 hours

    Subjects responded to Refreshing nature of sleep (10-point scale, where 1 was not refreshing and 10 was very refreshing)

  13. Subjective Sleep Questionnaire - Time to Fall Asleep Last Night

    Time frame: Up to 10 hours

    Subjects responded to Estimate of how long it took to fall asleep (minutes)

  14. Subjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed

    Time frame: Up to 10 hours

    Subjects responded to Estimate of the amount of time the subject was awake from the time he or she fell asleep until the time he or she got out of bed (hours and minutes)

  15. Change From Baseline in Pain Intensity

    Time frame: Baseline and up to 10 hours

    Pain Severity was collected on a 4-point categorical scale: 0=no pain, 1=mild pain, 2=moderate pain, 4=severe pain

  16. Overall Rating of Pain Relief

    Time frame: Up to 10 hours

    The Pain Relief Rating Scale was a 5-point categorical scale which included the following possible responses to the request to finish statement "Overall, the relief from my starting pain was": no relief (0); a little relief (1); some relief (2); a lot of relief (3); complete relief (4).

  17. Time to Rescue Medication

    Time frame: Up to 10 hours

    If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded

  18. Cumulative Proportion of Participants Taking Rescue Medication by Hour

    Time frame: Up to 10 hours

    If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded

  19. Global Assessment of Investigational Product as a Pain Reliever

    Time frame: Up to 10 hours

    The Global Assessment of Investigational Product as a Pain Reliever was a 5- point categorical scale which included the following possible responses: poor (0); fair (1); good (2); very good (3); excellent (4).

Other outcomes

  1. Vital Signs: Mean Change From Baseline in Systolic Blood Pressure at Day 2

    Time frame: Baseline and day 2

  2. Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure at Day 2

    Time frame: Baseline and Day 2

  3. Vital Signs: Mean Change From Baseline in Pulse Rate at Day 2

    Time frame: Baseline and day 2

  4. Vital Signs: Mean Change From Baseline in Respiratory Rate at Day 2

    Time frame: Baseline and day 2

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep

Acronym: Morpheus/DPH

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Dec 20, 2011
Registry last updated
Jun 8, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.